Provided by Tiger Fintech (Singapore) Pte. Ltd.

Adaptimmune Therapeutics PLC

0.0425
+0.00153.66%
Pre-market: 0.04320.0007+1.65%06:30 EDT
Volume:28.88M
Turnover:1.25M
Market Cap:11.26M
PE:-0.06
High:0.0460
Open:0.0403
Low:0.0403
Close:0.0410
52wk High:1.17
52wk Low:0.0403
Shares:265.05M
Float Shares:183.08M
Volume Ratio:0.85
T/O Rate:15.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6574
EPS(LYR):-0.2807
ROE:-1341.10%
ROA:-40.86%
PB:-0.16
PE(LYR):-0.15

Loading ...

Mar 24, 2025

Major Issues Report

Form 8-K - Current report
Mar 20, 2025

Major Issues Report

Form 8-K - Current report
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 17, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jan 15, 2025

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Dec 19, 2024

Major Issues Report

Form 8-K - Current report
Nov 14, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 14, 2024

Major Issues Report

Form 8-K - Current report
Nov 13, 2024

Major Issues Report

Form 8-K - Current report
Nov 13, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Nov 01, 2024

Major Issues Report

Form 8-K - Current report
Sep 23, 2024

Major Issues Report

Form 8-K - Current report
Aug 12, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2024

Major Issues Report

Form 8-K - Current report